Biomea Fusion is trading at $1.58, up 16.18% in after-hours trading, with no clear catalyst identified.
- No clear company-specific announcement on October 12 explains the after-hours rise; its latest listed press release was September 23.
- Brookline Capital’s Buy rating and $10 target were reported October 7, but that earlier analyst action does not establish the cause.
- Monday’s major indexes were mixed, so broad-market strength is not an evident explanation; the catalyst remains unclear.